CA Patent

CA2935013A1 — Pharmaceutical composition containing nitisinone, and its use

Assigned to Cycle Pharmaceuticals Ltd · Expires 2015-07-09 · 11y expired

What this patent protects

Disclosed are oral pharmaceutical compositions consisting of nitisinone, lactose, and glyceryl dibehenate, and their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria.

USPTO Abstract

Disclosed are oral pharmaceutical compositions consisting of nitisinone, lactose, and glyceryl dibehenate, and their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria.

Drugs covered by this patent

Patent Metadata

Patent number
CA2935013A1
Jurisdiction
CA
Classification
—
Expires
2015-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Cycle Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.